Delix Therapeutics Continues Rapid Growth with Appointment of Chief Medical Officer
BOSTON, Aug. 2, 2021 /PRNewswire/ -- Preclinical neuroscience company Delix Therapeutics (the "Company"), today announced the appointment of Dr. Brigitte Robertson as Chief Medical Officer.
- BOSTON, Aug. 2, 2021 /PRNewswire/ -- Preclinical neuroscience company Delix Therapeutics (the "Company"), today announced the appointment of Dr. Brigitte Robertson as Chief Medical Officer.
- Dr. Robertson joins the company from Yumanity Therapeutics, where she served as Chief Medical Officer since 2019.
- "Delix is fortunate to have Dr. Robertson and her unmatched experience developing scientifically rigorous medicines and safely bringing them to the market," said Delix Therapeutics CEO Mark Rus.
- Delix co-founder Dr. David E. Olson was named Chief Innovation Officer and head of Delix's Scientific & Strategic Advisory Board.